PRZOOM - /newswire/ -
Amherst, NH, United States, 2013/06/05 - Recently approved products and established autoimmune treatments will drive growth, according to Greystone Research Associates - GreystoneAssociates.org.
Therapeutic fusion proteins registered $6.7 billion in sales in 2012, according to a new study from Greystone Research Associates. The continued strong performances of Enbrel and Orencia and a trio of recently approved products will converge to drive this segment above $10 billion over the next four years.
Fusion proteins represent a special class of engineered biologicals that are designed to generate a highly specific therapeutic effect at a well-defined physiological site. The current generation of FDA-approved fusion proteins addresses indications in a range of conditions, led by autoimmunity. The three dozen fusion protein product candidates winding their way through the development process represent a much wider spectrum of therapeutic indications and protein engineering technology approaches.
The complexity of fusion proteins and the challenges related to their design, manufacture and packaging are fostering a multi-disciplinary approach among market participants that includes the incorporation of concurrent development principles to properly risk manage FP product programs. Cooperation between drug developers, packaging designers and delivery technologists is occurring much earlier in the drug development cycle, allowing product engineering to be tailored to the bioavailability targets and pharmacokinetic profiles of each specific drug therapy.
A new report researched and written by Greystone Research Associates Therapeutic Fusion Proteins to 2018 - provides detailed and comprehensive analysis of therapeutic markets for fusion proteins. The report assesses approved products, examines development stage candidates, analyzes market and regulatory factors, and profiles market sector participants.
Greystone Research Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.